Coltin Krauss

Coltin Krauss is Senior Director of Financial Planning & Analysis at the Parker Institute for Cancer Immunotherapy (PICI), having worked previously as a project budgeting consultant for the organization. In his expanded role, he will concentrate on corporate-wide strategic financial planning, budgeting, analysis and reporting.

Before joining PICI, Coltin was a finance consultant at Myovant Sciences, where he helped launch their first product, ORGOVYX, a prescription medicine for advanced prostate cancer. Before that, he served in various R&D finance roles

at Genentech/Roche Group.